Sponsor content
270 result(s) found, displaying 21 to 30
-
Australian Public Assessment Report (AusPAR)Lazcluze (lazertinib) in combination with amivantamab is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for DARZALEX daratumumab 100 mg/5 mL concentrated solution for infusion vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for DARZALEX daratumumab 400 mg/20 mL concentrated solution for infusion vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Cellular Therapies - T cells-Ciltacabtagene autoleucel, cryopreserved-T-CARVYKTI - Janssen-Cilag Pty Ltd - Injection, intravenous infusion - Bag.
-
Sep-2025Prescription medicine evaluationActive ingredient: ibrutinib.
-
-
Australian Public Assessment Report (AusPAR)TALVEY (talquetamab) has been provisionally approved for the treatment of adult patients with relapsed or refractory multiple myeloma.
-
Prescription medicine registrationActive ingredients: daratumumab.
-
-
Australian Public Assessment Report (AusPAR)Opsynvi (macitentan/tadalafil) is approved for maintenance treatment of pulmonary arterial hypertension in adult patients.